Exagen Overview
- Year Founded
-
2002
- Status
-
Public
- Employees
-
220
- Stock Symbol
-
XGN
- Investments
-
1
- Share Price
-
$4.13
- (As of Friday Closing)
Exagen General Information
Description
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
Contact Information
Website
www.exagen.comCorporate Office
- 1261 Liberty Way
- Vista, CA 92081
- United States
Corporate Office
- 1261 Liberty Way
- Vista, CA 92081
- United States
Exagen Stock Performance
As of 13-Nov-2026, Exagen’s stock price is $4.13. Its current market cap is $105M with 25.5M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.13 | $4.41 | $2.59 - $9.28 | $105M | 25.5M | 438K | -$0.76 |
Exagen Financials Summary
As of 30-Sep-2026, Exagen has a trailing 12-month revenue of $72.3M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 198,403 | 128,166 | 73,831 | 30,228 |
| Revenue | 72,295 | 66,575 | 55,641 | 52,548 |
| EBITDA | (10,937) | (13,339) | (11,656) | (20,081) |
| Net Income | (18,172) | (19,951) | (15,115) | (23,689) |
| Total Assets | 55,353 | 58,022 | 44,689 | 56,944 |
| Total Debt | 27,322 | 25,706 | 23,206 | 23,231 |
Exagen Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Exagen Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Exagen Comparisons
Industry
Financing
Details
Exagen Competitors (20)
One of Exagen’s 20 competitors is Biodesix, a Formerly VC-backed company based in Louisville, CO.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Biodesix | Formerly VC-backed | Louisville, CO | ||||
| CellMax Life | Venture Capital-Backed | Sunnyvale, CA | ||||
| Interpace Biosciences | Private Debt Financed | Parsippany, NJ | ||||
| NeoGenomics | Corporation | Fort Myers, FL | ||||
| Myriad Genetics | Corporation | Salt Lake City, UT |
Exagen Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Exagen Patents
Exagen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260140113-A1 | Protein biomarkers for use in lupus nephritis | Pending | 15-Nov-2024 | ||
| US-20240257930-A1 | Method for normalizing health related events (hres) count variables | Pending | 01-Feb-2023 | ||
| US-20240257964-A1 | Method for reducing dependency of non-discrete laboratory measurements results on personal parameters | Pending | 01-Feb-2023 | ||
| US-20240257972-A1 | Novel tool for clinical decision support in early autoimmune disease diagnosis | Inactive | 01-Feb-2023 | ||
| WO-2024081737-A1 | Biomarker selection for machine learning enabled prediction of treatment response | Inactive | 12-Oct-2022 | G16H50/20 |
Exagen Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Exagen Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Exagen Acquisitions (1)
Exagen’s most recent deal was a Merger/Acquisition with Cypress Bioscience (Diagnostic Business) for . The deal was made on 08-Oct-2010.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Cypress Bioscience (Diagnostic Business) | 08-Oct-2010 | Merger/Acquisition | Buildings and Property |
Exagen ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Exagen FAQs
-
When was Exagen founded?
Exagen was founded in 2002.
-
Where is Exagen headquartered?
Exagen is headquartered in Vista, CA.
-
What is the size of Exagen?
Exagen has 220 total employees.
-
What industry is Exagen in?
Exagen’s primary industry is Laboratory Services (Healthcare).
-
Is Exagen a private or public company?
Exagen is a Public company.
-
What is Exagen’s stock symbol?
The ticker symbol for Exagen is XGN.
-
What is the current stock price of Exagen?
As of 13-Nov-2026 the stock price of Exagen is $4.13.
-
What is the current market cap of Exagen?
The current market capitalization of Exagen is $105M.
-
What is Exagen’s current revenue?
The trailing twelve month revenue for Exagen is $72.3M.
-
Who are Exagen’s competitors?
Biodesix, CellMax Life, Interpace Biosciences, NeoGenomics, and Myriad Genetics are some of the 20 competitors of Exagen.
-
What is Exagen’s annual earnings per share (EPS)?
Exagen’s EPS for 12 months was -$0.76.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
